Mkts

NRX Pharmaceuticals, Inc.

NASDAQ: NRXP
$2.27-0.39 (-14.66%)
As of Oct 30, 4:00 PM ET

Key statistics

Day range
2.112.84
52-week range
1.625.05
Today
Open2.83
Previous close2.27
Volume—
Valuation
Market cap98.28M
P/E ratio—
EPS (TTM)-0.74
Income & risk
Dividend / yield—
Beta2.05
Avg volume1.03M
Discussion

NRXP News

Stories mentioning NRXP from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue1,068242.000.000.00
Cost of Goods Sold631.0097.000.000.00
Gross Profit437.00575.00145.000.000.000.000.000.00
Operating Expenses
Research & Development1,309557.001,429987.00804.001,036611.002,804
Sales General & Admin3,8132,8082,9432,409
Total Operating Expenses3,7302,4323,0227,050
Operating Income (Loss)(4,742)(4,623)(4,024)(3,730)(3,847)(2,432)(3,022)(7,050)
Interest Income5.004.002.002.004.004.006.007.00
Interest Expense
Other Expense
Pretax Income
Tax Provision0.000.00
Net Income (Loss)(1,430)361.00(5,890)(17,581)(5,512)(9,078)(1,623)(7,897)
Earnings Per Share (Basic)(0.04)0.02(0.27)(0.98)(0.34)(0.85)(0.15)(0.75)
Earnings Per Share (Diluted)
Weighted Average Shares Outstanding (Basic)32,32521,40222,23117,93416,41010,64410,97410,517
Weighted Average Shares Outstanding (Diluted)

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About NRXP

NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) is a stock listed on the Nasdaq Stock Market under the ticker symbol NRXP. It last traded at $2.27 (Oct 30, 2026, 4:00 PM ET), down 14.7% on the day. That gives NRX Pharmaceuticals a market capitalisation of $98.3M.

Over the past 52 weeks NRXP has traded between $1.62 and $5.05.

Revenue for the quarter ended Mar 31, 2026 was $1.1M; a net loss of $1.4M.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$1.1M-$1.4M-133.9%
Dec 31, 2025—$361.0K—
Sep 30, 2025$242.0K-$5.9M-2433.9%
Jun 30, 2025—-$17.6M—

From NRX Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…